The Institute of Protein Innovation welcomes esteemed industry leader Kenneth Vasman, Ph.D., as President and CEO

Boston – () –Institute of Protein Innovation (IPI), a nonprofit research organization advancing protein science to accelerate biomedical research and improve human health, today announced the appointment of Kenneth Fesman, Ph.D., as President and CEO. Dr. Fesman comes to IPI from The Jackson Laboratory (JAX), where he served as Senior Vice President for Research.

The IPI Board has recognized that Dr. Fesman’s unique experience in the academic, industrial, and non-profit sectors will facilitate the Institute’s mission and ambition. The IPI aims to provide protein-based research resources and tools, advance protein science through investigator-driven research and further educate life scientists. Specifically, Dr. Fisman will lead IPI in:

  • Scaling the IPI synthetic recombinant antibody platform to serve large-scale scientific communities through antibody collaboration and antibody distribution.

  • Implementation of a sustainable model of independent research by IPI faculty and colleagues enhances the platform and applies protein tools and methods to a deeper understanding of human biology and disease.

  • Develop an educational program to promote and disseminate the latest in protein science.

There are not many institutions that aim to be a world-class academic research organization and a sustainable, not-for-profit provider of resources, tools, and services to the life sciences community,” said Dr.I can bring my expertise to foster the creative partnership between these two components. Our goal is to have the same impact on protein science that institutions like the Broad or Sanger Institutes have done for genomics.”

As a leader in collaborative scientific research and management of technology platforms for biomedical research, Dr. Fesman led Informatics R&D, drug development strategy and performance at AstraZeneca and served as Chief Scientific Officer at the Adelson Medical Research Foundation before joining JAX in 2015. Dr. Fasman holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine and BA in Electrical Engineering and Computer Science from Princeton University.

His arrival at the IPI comes at an opportune time for the growth of the organization. The institute was founded in 2017 by Harvard Medical School professors Timothy Springer, Ph.D., and Andrew Cross, Ph.D., and was launched by the philanthropic work of Dr. Springer.

Over the past two years, IPI has improved its technology and more clearly targeted its antibody platform to serve the scientific community in areas such as neuroscience, where traditional antibodies are lacking, said Rob Myers, PhD, IPI’s interim executive director and director. from the antibody platform. “On behalf of IPI and its board, I welcome Beijing to take us to the next chapter, to expand our faculty and prepare us for our antibody distribution. ”

IPI strengthens the board of directors

To further direct IPI towards development and expansion, appointed IPI Samantha Singer, MBAChairman of the Board of Directors was elected Stephen Blacklow, MD, PhD.As a new member of the Board of Directors.

Ms. Singer is an experienced biotechnology leader with more than two decades of experience in start-ups, corporate development and operations. She is currently the President and CEO of Abata Therapeutics and is a former Board Member of 5:01 Special Acquisition Corp. Previously, Ms. Singer was a resident entrepreneur at Third Rock Ventures, specializing in creating a business across the company’s portfolio. Her previous roles include Chief Operating Officer at The Broad Institute and Vice President of Corporate Strategy and Chief of Staff at Biogen Inc.. Ms. Singer holds an MSc in Molecular Biology from Rockefeller University and an MBA from Harvard Business School.

The most important factors in building biotechnology, whether it is a non-profit or for-profit, is having a compelling mission, getting great people behind it and creating an environment in which they can thrive and achieve the vision,” says Ms. Singer.IPI has this task. She has a Tim Springer vision. Now he has Ken’s talent and experience as a top-tier CEO. I am excited to be part of this team.”

Dr. Bellalo is Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and a member of the Division of Cancer Biology at the Dana-Farber Cancer Institute. Received the prestigious National Cancer Institute Distinguished Investigator Award, Dr. Bellalo was elected to the American Physicians Association in 2018. Dr. Bellalo holds an MD and Ph.D. He received his Ph.D. in organic biochemistry from Harvard University, completed his residency in clinical pathology at Brigham and Women’s Hospital, and did postdoctoral research at the Whitehead Institute for Biomedical Research.

“I believe in the purpose and mission of IPI,” says Dr. Bilalow.By going far beyond providing a repertoire of antibodies to the scientific community, IPI is poised to be uniquely innovative and innovative in the field of protein science.”

Save the date

To celebrate progress and share its vision for the next stage of development, IPI is pleased to announce that it will be hosting its first symposium. The event, titled “IPI Surfacing”, will be an in-person scientific encounter with talks and discussions from leading scientists around the world, including Christopher Garcia, Ph.D., from Stanford University, Yvonne Jones, Ph.D., from the University of Oxford, Andreas Blockthon. , Ph.D., from the University of Zurich and Junichi Takagi, Ph.D., from Osaka University. The symposium will take place at the Joseph B. Martin Convention Center, Harvard Medical School, Boston, MA, on June 15, 2023. Additional event details will be shared in the coming months.

About IP

The Protein Innovation Institute (IPI) is the pioneer in a new approach to scientific discovery and collaboration. As a non-profit research institute, we provide academia and industry with synthetic antibodies and deep protein expertise, enabling researchers to unlock the most elusive mysteries of biology. Our mission is to advance protein science to accelerate research and improve human health.

Leave a Comment